The Latin America, Middle East and Africa Herpes Simplex Virus Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2022-2028).
As HSV infection is more likely to reactivate in the first few months following solid organ and bone marrow transplants, the rise in the number of transplant recipients is a factor in the market's expansion. In accordance with this, researchers are concentrating on creating novel antiviral drugs to increase the range of available treatments for genital and orolabial herpes. Also, they are bringing out antiviral creams or ointments that can lessen HSV-related itching, burning, or tingling sensations, enhance the quality of life (QoL) of patients, and stop infected persons from transmitting the virus.
Many people have HSV that is asymptomatic, which means they carry the virus but have never experienced a herpes outbreak or active episode. Others may occasionally get sores or blisters that are tiny and filled with fluid. These blisters can appear on the hands, fingers, or other body parts but typically on the genitalia, mouth, or lips. The herpes virus can be spread through sexual contact, but other ways exist. Herpes carries a lot of stigmas, yet the virus is fairly widespread. As more people are becoming aware of this, the demand for HSV medication is rising.
Latin America has a high HSV-2 seroprevalence. An estimated 20% to 60% of people are infected. Middle-aged Colombian women were found to have the highest HSV-2 frequency in the region. In Brazil, women are more likely to contract HSV-2 if their male partners have a record of anal sex and have had numerous sexual partners during their lifetime. As a result, many regional governments have increased their efforts to mitigate the burden of the disease as well as increase the awareness about it among the general public. The government's provision of HSV treatment at affordable costs is among these efforts. Consequently, such efforts significantly boost the market expansion in this region.
The Brazil market dominated the LAMEA Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $47.6 Million by 2028. The Argentina market is experiencing a CAGR of 7.2% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 6.3% during (2022 - 2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Herpes Simplex Virus Treatment Market is Projected to reach USD 2.1 Billion by 2028, at a CAGR of 3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
By Drug Type
By Type
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
